Medical Condition News

RSS

Intravenous aspirin safe, effective option for severe headache or migraine

A new study shows that aspirin, given intravenously (IV), may be a safe and effective option for people hospitalized for severe headache or migraine, undergoing medication withdrawal. The research will be published in the September 21, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.

21 Sep 2010

Study: Capecitabine with concurrent radiation is effective for treating gastric cancer

Gastric cancer is a major cause of cancer deaths in the world. The outcome of large gastric tumors and those with lymph node involvement remains poor after surgical resection. The optimal adjuvant therapy after surgical resection remains to be determined.

21 Sep 2010

FG-4592 oral anemia therapy receives CTA approval from SFDA

FibroGen, Inc., today announced that its investigational oral anemia therapy, FG-4592, received Clinical Trial Application (CTA) approval from the Chinese State Food and Drug Administration (SFDA) to commence clinical development for the treatment of anemia associated with chronic kidney disease (CKD) in the People's Republic of China.

21 Sep 2010

Danya International unveils new website for autism spectrum disorders

Danya International, Inc. (Danya), a communications, research, and technology company, unveils the new AutismOnline.com Web site encompassing research-based products and resources for individuals of all ages with autism spectrum disorders (ASD). The AutismOnline.com Web site was introduced during a launch event today at the historic AFI Silver Theatre and Cultural Center in Silver Spring, Maryland.

21 Sep 2010

FDA Advisory Committee recommends approval of dabigatran etexilate for stroke prevention in AFib patients

The U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee today voted 9 to 0 in favor of approving dabigatran etexilate for stroke prevention in patients with atrial fibrillation (AFib). An estimated 2.3 million Americans have AFib and the prevalence is expected to increase 2.5 fold to 5.6 million by 2050, reflecting the growing population of elderly individuals.

21 Sep 2010

Six3 gene safeguards future retina

New research led by St. Jude Children's Research Hospital investigators adds to evidence that the Six3 gene functions like a doorman in the developing brain and visual system, safeguarding the future retina by keeping the region where the eye is forming free of a signaling protein capable of disrupting the process.

21 Sep 2010

Clemson biochemist receives grants to study DNA repair pathways

A Clemson biochemist has received grants totaling $787,000 to study how cells repair damaged DNA, which can cause cancer and genetic illnesses. The U.S. Department of Defense (DoD) and the National Institutes of Health (NIH) awarded Weiguo Cao three-year funding to investigate two DNA repair pathways.

21 Sep 2010

NQF endorses 8 outcome measures for pulmonary, cardiovascular conditions and care provided in ICU

To improve healthcare quality and give patients and providers more information about the results of care, the National Quality Forum (NQF) has endorsed eight outcome measures for pulmonary and cardiovascular conditions and care provided in the intensive care unit (ICU). This is the first in a set of patient outcome measures NQF is reviewing.

20 Sep 2010

Biomarkers may help predict children at high risk of developing type 2 diabetes

Children who have a high risk of developing type 2 diabetes might be identified earlier by way of tell-tale genetic indicators known as biomarkers. Some of those new biomarkers might be pinpointed in research led by Nancy F. Butte and funded by the U.S. Department of Agriculture (USDA) and the U.S. Department of Health and Human Service's National Institutes of Health.

20 Sep 2010

Researchers identify protein essential for dendritic cell development

A protein called PU.1 is essential for the development of dendritic cells, the sentinels of the immune system, Walter and Eliza Hall Institute researchers in Melbourne, Australia, have shown.

20 Sep 2010

MJFF selects Epitomics to distribute LRRK2 monoclonal antibodies

Epitomics, Inc. today announced that The Michael J. Fox Foundation for Parkinson's Research (MJFF) has chosen the company to distribute a panel of LRRK2 monoclonal antibodies that were developed under an agreement between the two parties. Under a special arrangement the antibodies are being provided at low cost to the entire PD research community to help advance LRRK2 therapeutic development efforts. The antibodies will be available to Parkinson's researchers in academic/nonprofit and industry labs on a worldwide basis.

20 Sep 2010

New body-contouring laser causes fat loss

Stephanie Martinez had one of the most universal desires - to shed a few stubborn inches from her waist, hips and thighs - without harsh diets, needles or other surgical interventions that require staying at home and taking time off from work.

20 Sep 2010

Genzyme announces Japanese approval of Synvisc viscosupplement for OA knee pain relief

Genzyme Corporation announced today that Japan's Ministry of Health, Labour and Welfare has approved Synvisc® (hylan G-F 20; 3 x 2 mL), indicated for the treatment of osteoarthritis of the knee. Reimbursement has been obtained and publicized by Japan's Central Social Insurance Medical Council.

20 Sep 2010

NIAMS awards $684,000 SBIR grant to Signum Biosciences to develop GPCR modulating therapeutics

Signum Biosciences, Inc. was recently awarded two Small Business Innovation Research (SBIR) Phase I grants by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the NIH, totaling over $684,000 for development of novel G-protein coupled receptor (GPCR) modulating therapeutics designed to treat common skin disorders.

20 Sep 2010

Harbor BioSciences granted US patent for Triolex metabolic disease and anti-inflammation drug candidate

Harbor BioSciences, Inc. today announced that the company has received patent No. 7,776,845 from the United States Patent and Trademark Office which covers its lead metabolic disease and anti-inflammation drug candidate Triolex (HE3286). The patent claims cover compounds including Triolex and formulations that contain the drug or the other claimed compounds.

20 Sep 2010

Seven abstracts on Lantheus' PET imaging candidates to be presented at ASNC2010

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that seven abstracts related to two of the company's cardiac Positron Emission Tomography (PET) imaging candidates will be presented at ASNC2010, the 15th Annual Scientific Session of the American Society of Nuclear Cardiology, being held September 23-26, 2010 in Philadelphia.

20 Sep 2010

St. Jude Medical granted European CE Mark for Athena deep brain stimulation therapy management system

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its new Athena™ programmer, a deep brain stimulation (DBS) therapy management system. This next-generation platform offers clinicians a powerful yet easy-to-use interface that enables them to set or adjust therapeutic parameters to optimize patient results.

20 Sep 2010

Walmart, CVS to sell NEW Handheld Power Pill Grinder for dysphagia patients

Variant Products Ltd. announced today that walmart.com and cvs.com will soon be selling its NEW Handheld Power Pill Grinder. It is significant because sales velocities are being closely monitored by both retailers for store consideration. Validating the market, Walmart and CVS currently dedicate resources to educate and address dysphagia concerns (difficulty swallowing). People who struggle with this issue often crush or grind their meds/supplements and the Power Pill Grinder offers a unique alternative to traditional manual crushers.

20 Sep 2010

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

Celera Corporation and Abbott today announced that they have signed an exclusive distribution agreement to market Celera's CE-marked KIF6 diagnostic test for use on Abbott's CE-marked m2000™ instrument system. The KIF6 genotyping assay detects a genetic marker that may be used in conjunction with clinical evaluation and patient assessment for the identification of individuals at risk for coronary heart disease (CHD), and in patients for whom statin treatment is being considered.

20 Sep 2010

Micromet initiates MT103 phase 2 trial in adult ALL patients

Micromet, Inc. today announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells.

20 Sep 2010